Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT02838745
- Locations
- 🇺🇸
Baylor St Lukes, Houston, Texas, United States
A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT02825940
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology, Guangzhou City, China
Chemoembolization for Hepatocellular Carcinoma
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 24
- Registration Number
- NCT02821533
- Locations
- 🇭🇰
Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 28
- Registration Number
- NCT02819999
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University Hospital of Cleveland, Cleveland, Ohio, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
- Conditions
- Neoplasms
- Interventions
- Drug: TSR-022Drug: TSR-042Drug: NivolumabDrug: TSR-033Drug: DocetaxelDrug: PemetrexedDrug: CisplatinDrug: Carboplatin
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT02817633
- Locations
- 🇨🇳
GSK Investigational Site, Tainan, Taiwan
Trial of BMS-986012 in Combination With Platinum and Etoposide
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT02815592
- Locations
- 🇪🇸
Local Institution - 0002, Barcelona, Spain
🇪🇸Local Institution - 0004, Madrid, Spain
🇪🇸Local Institution - 0010, Malaga, Spain
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1213
- Registration Number
- NCT02807636
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇦🇺Lyell McEwin Hospital, Adelaide, South Australia, Australia
🇨🇦Dr. Georges L. Dumont University Hospital Centre, Moncton, New Brunswick, Canada
Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Radiation: Carbon ion radiotherapy (CIRT)Drug: Cisplatin
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Shanghai Proton and Heavy Ion Center
- Target Recruit Count
- 6
- Registration Number
- NCT02801487
- Locations
- 🇨🇳
Shanghai Proton and Heavy Ion Center, Shanghai, Shanghai, China
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
- Conditions
- Advanced/Metastatic Tumors
- Interventions
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 518
- Registration Number
- NCT02794571
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
High-Risk Neuroblastoma Chemotherapy Without G-CSF
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT02786719
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.